Samsung Biologics Acquires Swiss Peptide Maker for $1.8 Billion

Samsung Biologics has redefined its aggressive expansion strategy in biotechnology by acquiring a Swiss peptide maker for $1.8 billion.

A New Equilibrium in the Peptide Landscape

Strategic Rationale and Financial Details

■Samsung Biologics purchased Lonza’s peptide unit for $1.8 billion.

■The deal includes a 15% premium and is slated to close by the end of 2024.

■The acquisition will boost Samsung’s biosimilar and peptide‑based therapy capacity by roughly 30%.

Market Impact and Competitive Landscape

■Analysts expect Samsung Biologics shares to rise about 8% in the near term following the news.

■Competitors such as Lonza and Catalent are likely to reassess their peptide investments.

■U.S. and European regulators will monitor the consolidation of the peptide supply chain.

The consolidation of the peptide market erodes the cost advantage of chemically synthesized molecules, pushing biotech production toward deeper integration; over the long haul, this could accelerate a shift toward specialized manufacturing hubs that support high‑performance chip demand seen at firms like Nvidia.